Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS
Acumen Pharmaceuticals — Q3 2022 Earnings Presentation
6 slides from Acumen Pharmaceuticals's earnings presentation, Nov 14, 2022
Slide 1: Q3 2022 Financial Results & Business Update
Q3 2022 Financial Results & Business Update Nov. 14, 2022 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and
Slide 3: Agenda
Agenda • Q3 2022 Business Update Dan O’Connell, Chief Executive Officer • ACU193 Momentum and Alzheimer’s Landscape Update Dr. Eric Siemers, Chief Medical Officer • Q3 2022 Financial Results Matt Zuga, Chief Business Officer & Chief Financial Officer 3
Slide 4: INTERCEPT-AD Trial Update – 3Q 2022
INTERCEPT-AD Trial Update – 3Q 2022 • INTERCEPT-AD: Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease (AD) (RCT) → Trial enrollment ongoing at 17 active sites ▪ Enrollment completion expected in 1Q 2023 → Topline results (proof-of-mechanism) following full database lock exp
Slide 5: ACU193 Fast Track Designation and Clinical Development Plan
ACU193 Fast Track Designation and Clinical Development Plan • In October 2022, ACU193 granted Fast Track designation for the treatment of early Alzheimer’s disease by the U.S. Food and Drug Administration (FDA) → Reflects potential clinical utility of ACU193 to treat early AD • Also in October 2022,
Slide 6: Acumen is Well Capitalized, With Expected Cash Runway Through 2025
Acumen is Well Capitalized, With Expected Cash Runway Through 2025 STATUS/ MILESTONES EXPECTED TIMING ~$200M Initiated Ph1 clinical trial INTERCEPT-AD ✓ Cash, cash equivalents and marketable securities as of INTERCEPT-AD enrollment complete 1Q 2023 September 30, 2022 Proof-of-mechanism topline resul
Acumen Pharmaceuticals — Q3 2022 Earnings Presentation on 6ix